Core Insights - The article highlights the increasing federal focus on deep brain neurostimulation as a promising therapy for conditions such as TBI, PTSD, stroke recovery, and Alzheimer's disease, with Nexalin Technology, Inc. playing a significant role in this emerging field [1][4][10] Legislative Developments - Recent bipartisan Congressional initiatives have expanded federal support for deep brain neurostimulation research, particularly through the U.S. Department of Veterans Affairs (VA) and the National Institutes of Health (NIH) [1][4] - H.R. 7091, introduced on January 15, 2026, aims to expand clinical trials for deep brain neurostimulation and establish a compassionate use pathway within the VA system [7] - The Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026, includes provisions for neuromodulation research focused on stroke recovery among veterans, signed into law by President Trump [7] - The Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026, expands NIH-supported research using deep brain stimulation for Alzheimer's and Parkinson's diseases, also signed into law by President Trump [7] Company Initiatives - Nexalin Technology's DIFS™ technology is recognized as a sophisticated form of non-invasive deep brain neurostimulation and is currently being evaluated in research with UC San Diego and the San Diego VA veterans' community [2][5] - The company is actively engaged in policy advocacy to support the inclusion of deep brain neurostimulation in federal legislation, which has raised awareness of its therapeutic potential among policymakers [8][9] - Nexalin believes that the expanding federal support for neuromodulation research aligns with its strategic focus on developing non-invasive technologies to address significant unmet medical needs [5][9] Market Opportunity - Conditions such as TBI, PTSD, stroke-related neurological impairment, Alzheimer's disease, and Parkinson's disease represent multi-billion-dollar addressable markets with significant unmet medical needs [10] - As federal research initiatives expand, Nexalin is positioned to advance emerging neurostimulation therapies within the VA system and the broader healthcare infrastructure [10][11]